BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) (NASDAQ:VRTX). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by Vertexbetween May 7, 2012 and May 29, 2012, concerning the Company’s operations and financial prospects.

Vertexis engaged in discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The Company markets Kalydeco in the United States and European Union as a treatment for patients aged six years and older with a rare form of cystic fibrosis. The investigation is related to allegations that the Company misrepresented or failed to disclose material information concerning the clinical development of Kalydeco in combination with another product, VX-809.

On May 29, 2012, the Company issued a correction of the interim analysis of the Phase 2 Combination Study of VX-809 and Kalydeco, stating that the correction was due to a “misinterpretation” between Vertex and a third-party statistical analysis vendor over the study data.

If you purchased Vertex common stock between May 7, 2012 and May 29, 2012, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.